The Lancet Regional Health: Western Pacific最新文献

{"title":"Methodological considerations in CKM risk stratification: age validation of PREVENT—authors' reply","authors":"Yesol Yim , Yejun Son , Dong Keon Yon","doi":"10.1016/j.lanwpc.2025.101614","DOIUrl":"10.1016/j.lanwpc.2025.101614","url":null,"abstract":"","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"60 ","pages":"Article 101614"},"PeriodicalIF":7.6,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144366399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physical activity and air pollution: context matters for cardiovascular health","authors":"Omar Hahad , Sadeer Al-Kindi","doi":"10.1016/j.lanwpc.2025.101612","DOIUrl":"10.1016/j.lanwpc.2025.101612","url":null,"abstract":"","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"60 ","pages":"Article 101612"},"PeriodicalIF":7.6,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144338314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The ASEAN genome consortium: advancing equitable precision medicine through regional solidarity","authors":"Teguh Haryo Sasongko , Gunadi , Boon Peng Hoh , Jusaku Minari , Shih Wee Seow , Vorasuk Shotelersuk","doi":"10.1016/j.lanwpc.2025.101611","DOIUrl":"10.1016/j.lanwpc.2025.101611","url":null,"abstract":"","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"60 ","pages":"Article 101611"},"PeriodicalIF":7.6,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144321705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients” The Lancet Regional Health—Western Pacific, Volume 55 (2025), 101464","authors":"Yuji Hiromatsu , Eri Ishikawa , Ai Kozaki , Yasuhiro Takahashi , Mika Tanabe , Ken Hayashi , Yukihiro Imagawa , Kazutoyo Kaneda , Masashi Mimura , Xiaoxian Dai , Tomoko Hayashida , Takashi Akamizu","doi":"10.1016/j.lanwpc.2025.101607","DOIUrl":"10.1016/j.lanwpc.2025.101607","url":null,"abstract":"","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"60 ","pages":"Article 101607"},"PeriodicalIF":7.6,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144306510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding and mitigating cancer-related financial toxicity in China: challenges and recommendations","authors":"Weijie Xing , Zhenqi Lu , Yuhan Lu , Huiying Qin , Juan Xie , Qiongyao Guan","doi":"10.1016/j.lanwpc.2025.101601","DOIUrl":"10.1016/j.lanwpc.2025.101601","url":null,"abstract":"","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"60 ","pages":"Article 101601"},"PeriodicalIF":7.6,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144297482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Healthier SG: a gateway for evolving public-private-population partnerships in population health","authors":"Chuan De Foo ,&nbsp;Ting Hui Woon ,&nbsp;Hui Xiang Chia ,&nbsp;Jason Chin Huat Yap ,&nbsp;Wei Sheng Lee ,&nbsp;Chien Earn Lee ,&nbsp;Jose M. Valderas ,&nbsp;Clive Tan ,&nbsp;Ken Wah Teo","doi":"10.1016/j.lanwpc.2025.101606","DOIUrl":"10.1016/j.lanwpc.2025.101606","url":null,"abstract":"<div><div>Singapore’s primary healthcare landscape is dominated by private sector general practitioners, who have more room to play in terms of safeguarding the health of the population. Through a transformative national policy, Healthier SG, Singapore is evolving its health system to lean on private-public partnerships. This is achieved through shared care protocols, interoperable IT requirements, new models of financing, shared responsibilities and human resources and, importantly, a bidirectional feedback channel. The Ministry of Health has attempted to address most of the pressing issues that prevent private sector general practitioners from enrolling into this newly implemented national primary care policy but continues to face unintended challenges. Disjointed and misplaced expectations between stakeholders, arduous administrative requirements that GPs need to perform to get their reimbursement, cherry-picking simpler patients to enrol as it makes more business sense and the prospect of continued care fragmentation are some of the loops that this national policy will need to jump through.</div></div>","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"60 ","pages":"Article 101606"},"PeriodicalIF":7.6,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144297481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A decade of Benzodiazepine and Z-drug use in Hong Kong: a longitudinal study","authors":"Kyung Jin Lee ,&nbsp;Yue Wei ,&nbsp;Shek-Ming Leung ,&nbsp;Caige Huang ,&nbsp;Hei Hang Edmund Yiu ,&nbsp;Eunice Kehui Deng ,&nbsp;David J. Castle ,&nbsp;Simon S.Y. Lui ,&nbsp;Vincent K.C. Wong ,&nbsp;Ian C.K. Wong ,&nbsp;Esther W. Chan","doi":"10.1016/j.lanwpc.2025.101591","DOIUrl":"10.1016/j.lanwpc.2025.101591","url":null,"abstract":"<div><h3>Background</h3><div>Concerns are growing about the long-term use of benzodiazepines (BZDs) and non-benzodiazepines (Z-drugs) due to adverse effects such as drug tolerance, dependence, cognitive dysfunction, and falls, particularly in the elderly. This study aims to understand thorough prescribing patterns of BZDs and Z-drugs across age groups in clinical settings of Hong Kong, especially the long-term prescriptions.</div></div><div><h3>Methods</h3><div>Using territory-wide electronic health record data from Hong Kong (2014–2023), we analysed the prevalence, incidence, and duration of BZD and Z-drug prescriptions in adults. Long-term use was defined as prescriptions exceeding 90 days. Joinpoint regression models assessed trend changes, focusing on four age groups: 18–25, 26–49, 50–64, and ≥65. Psychiatric diagnoses within 180 days before and after treatment initiation were also evaluated.</div></div><div><h3>Findings</h3><div>Patients with BZD and Z-drug prescribing increased from 2014 to 2023, with an average annual percentage change (AAPC) of 3.44 [95% CI: 3.26–3.61] in prevalence and 1.51 [0.64–2.45] in incidence. Trends varied by age: the sharpest increases were observed in young adults aged 18–25 (prevalence AAPC: 9.43 [8.36–10.51]; incidence AAPC: 7.56 [6.19–8.89]), whereas the incidence in those aged ≥65 declined after 2019, although it remained the highest. Prevalence of patients with long-term prescribing rose consistently, particularly in young adults (BZD AAPC: 13.43 [11.98–14.62]; Z-drug AAPC: 12.88 [7.85–18.24]). Depression and dementia were the most common psychiatric diagnoses within 180 days before and after treatment initiation.</div></div><div><h3>Interpretation</h3><div>These findings highlight the need to review long-term prescribing practices and establish clear guidelines for safe BZD and Z-drug use, especially among young adults.</div></div><div><h3>Funding</h3><div>No funding has been provided for this research.</div></div>","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"59 ","pages":"Article 101591"},"PeriodicalIF":7.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144240208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The emerging clinical utility of ctDNA to guide adjuvant treatment in cancer","authors":"Emma Sanderson ,&nbsp;Peter Gibbs ,&nbsp;Jeanne Tie","doi":"10.1016/j.lanwpc.2025.101595","DOIUrl":"10.1016/j.lanwpc.2025.101595","url":null,"abstract":"","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"59 ","pages":"Article 101595"},"PeriodicalIF":7.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144221244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myopia and high myopia trends in Chinese children and adolescents over 25 years: a nationwide study with projections to 2050","authors":"Zhe Pan ,&nbsp;Haocheng Xian ,&nbsp;Feng Li ,&nbsp;Ziyao Wang ,&nbsp;Zihan Li ,&nbsp;Yu Huang ,&nbsp;Wenqing Liu ,&nbsp;Yiman Li ,&nbsp;Fan Li ,&nbsp;Jinyuan Wang ,&nbsp;Haichao Chen ,&nbsp;Yilan Wu ,&nbsp;Yueyuan Xu ,&nbsp;Gangyue Wu ,&nbsp;Yang Zhang ,&nbsp;Lvfu He ,&nbsp;Jianping Zhang ,&nbsp;Fangxia Zhang ,&nbsp;Xuehan Qian ,&nbsp;Xiuhong Zhang ,&nbsp;Tien Yin Wong","doi":"10.1016/j.lanwpc.2025.101577","DOIUrl":"10.1016/j.lanwpc.2025.101577","url":null,"abstract":"<div><h3>Background</h3><div>The global rise in myopia, particularly in Asia, presents significant public health challenges. Analyzing trends and forecasting impacts are critical for developing strategies to mitigate this burden.</div></div><div><h3>Methods</h3><div>We conducted the largest study to date on myopia and high myopia prevalence in Chinese children and adolescents aged 7–18 years, analyzing data from 5,095,256 individuals across 119 studies from 1998 to 2022. Data variability between cycloplegia and non-cycloplegia measurements was addressed using a distance-based model averaging calibration. Aggregated prevalence and age-specific urban-rural trends were estimated using thin plate spline regression, with projections to 2050 derived from time series modeling.</div></div><div><h3>Findings</h3><div>Myopia prevalence plateaued in 2006 in urban areas and in 2013 in rural areas, with the urban-rural prevalence gap narrowing since 2015 (urban/rural ratio below 1.3 for all ages). By 2050, myopia prevalence is projected to stabilize at 27.1% (95% CI: 10.0–44.4%) for ages 7–9 and 81.5% (74.7–88.3%) for ages 16–18 in urban areas, and at 20.1% (8.6–31.7%) and 74.1% (63.2–84.8%), respectively, in rural areas. High myopia prevalence among adolescents aged 16–18 is expected to rise from 7.3% in 2001 to 22.1% by 2050. Prevalence correlated significantly with the Human Development Index (P &lt; 0.001).</div></div><div><h3>Interpretation</h3><div>Despite stabilization in overall myopia prevalence, the continued rise in high myopia underscores the need for targeted control measures. Projections emphasize the importance of addressing regional disparities and prioritizing public health interventions.</div></div><div><h3>Funding</h3><div><span>National Natural Science Foundation of China</span> (<span><span>#82271086</span></span>; <span><span>#82388101</span></span>; <span><span>#72495123</span></span>).</div></div>","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"59 ","pages":"Article 101577"},"PeriodicalIF":7.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144263859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Capturing the complete clinical spectrum and incidence of severe acute Group A Streptococcus (GAS) disease: a population-based study in Auckland, New Zealand","authors":"Andrew Fox-Lewis ,&nbsp;Kate Wong She ,&nbsp;Emma Wong She ,&nbsp;Avinash Sathiyaseelan ,&nbsp;Anna Vesty ,&nbsp;Sally A. Roberts ,&nbsp;Susan C. Morpeth ,&nbsp;Susan Taylor ,&nbsp;Anneka Anderson ,&nbsp;Julie Bennett ,&nbsp;Nicole J. Moreland ,&nbsp;Rachel Webb","doi":"10.1016/j.lanwpc.2025.101600","DOIUrl":"10.1016/j.lanwpc.2025.101600","url":null,"abstract":"<div><h3>Background</h3><div>The global health burden of <em>Streptococcus pyogenes</em> (Group A <em>Streptococcus</em>, GAS) disease has led the World Health Organization to declare GAS vaccine development an international priority. Severe acute GAS disease comprises hospitalised infections, toxin-mediated disease (scarlet fever and streptococcal toxic shock syndrome) and immune-mediated disease (acute rheumatic fever [ARF] and acute post-streptococcal glomerulonephritis). This study aimed to characterize the burden and spectrum of severe acute GAS disease in Auckland, New Zealand, to inform future GAS vaccine studies in this setting.</div></div><div><h3>Methods</h3><div>This prospective population-based multicentre cross-sectional observational study utilized laboratory data and ARF notifications to capture all hospitalised GAS infections and toxin- and immune-mediated disease cases associated with hospitalisation in Auckland during 2023. The epidemiology, clinical features, incidence and hospitalisation costs of these cases are described.</div></div><div><h3>Findings</h3><div>The complete clinical spectrum of severe acute GAS disease was observed, with 606 cases captured corresponding to 1:2000 people affected each year (52 cases/100,000 population/year). The burden is inequitably distributed across the population, greatest at the intersection of age, ethnicity and socioeconomic deprivation. In the most deprived areas, approximately 1:400 Pacific children &lt;10-years and 1:200 Pacific adults ≥80-years are affected annually (261 and 483 cases/100,000 population/year, respectively). Direct hospitalisation costs exceeded $13·2 million New Zealand dollars.</div></div><div><h3>Interpretation</h3><div>This study demonstrates that the complete clinical spectrum of severe acute GAS disease occurs in Auckland and is associated with a substantial health and economic burden. The high incidence and entire range of severe acute GAS disease present make Auckland an ideal location for future vaccine studies.</div></div><div><h3>Funding</h3><div><span>Ministry of Health New Zealand</span>, <span>Health Research Council of New Zealand</span> (HRC-NZ), <span>Royal College of Pathologists of Australasia</span> (RCPA) Foundation.</div></div>","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"59 ","pages":"Article 101600"},"PeriodicalIF":7.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144263860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}